Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...

Fintel reports that on April 2, 2025, Leerink Partners upgraded their outlook for Compass Therapeutics (NasdaqCM:CMPX) from Market Perform to Outperform. Analyst Price Forecast Suggests 419.11% Upside ...

Trump has repeatedly called April 2 “Liberation Day,” alluding to a more sweeping and aggressive set of tariffs. Leerink ...

In a report released on March 31, Andrew Berens from Leerink Partners maintained a Hold rating on IDEAYA Biosciences (IDYA – Research Report).

Analysts at Leerink Partnrs upped their FY2025 earnings estimates for shares of AxoGen in a research note issued to investors ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (NasdaqCM:EQ) from Outperform ...

Leerink Partners analyst Puneet Souda maintained a Hold rating on Hologic (HOLX – Research Report) on March 28. The company’s shares opened ...

This is CNBC’s live coverage of President Donald J. Trump’s announcement of new tariffs targeting U.S. trade partners on ...

AirSculpt Technologies (NASDAQ:AIRS – Get Free Report) had its price target decreased by equities research analysts at Leerink Partners from $6.50 to $2.50 in a research note issued to investors on ...

SAN DIEGO, March 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida. Dr. Brady’s ...